Although it will be impacted in the short term by the COVID-19 pandemic, the biosurgical agent market in Japan will grow at a moderate rate through 2029, driven by rising surgical procedure volumes, the introduction of new products, and expanding indications for the existing products.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for Biosurgical Agents in Japan across a 10-year period.
The COVID-19 pandemic will affect the Japanese biosurgical agent market.
Which surgical specialties will be most impacted?
At what pace is the biosurgical agent market expected to recover?
The biosurgical agent market is driven by trends in surgical procedure volumes.
Which specialties are the strongest drivers of the market and why?
How will procedure trends be affected by technological advancements in surgical techniques?
Competitors are expanding their portfolios and investing in clinical trials.
Which companies lead the market and how are they promoting their products?
What strategies are used by smaller players to enter the market and compete with existing products?
Few biosurgical agents are available in the Japanese market.
Which segments have limited products available and what are the unmet needs?
Which segments are growing and what are the potential opportunities for market entry?
- Biosurgical Agents - Market Insights - Japan
Author(s): Sumit Jain, MS Pharm; Dhara Patel, MS Pharm
Sumit Jain is a senior analyst within the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at Decision Resources Group, focusing on diagnostic imaging capital equipment and healthcare IT markets. Sumit holds a Bachelor's degree in Pharmacy from the Rajiv Gandhi Technical University, Bhopal, and a Master's degree in Pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Mohali.
Dhara Patel is a research associate on the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at DRG (Part of Clarivate), specializing in capital equipment such as infusion systems and healthcare IT markets. Dhara holds a Bachelor's degree in Pharmaceutical Sciences from the University of Mumbai and a Master's degree in Medicinal Chemistry from the National Institute of Pharmaceutical Education and Research, Mohali.